Nancy Agee Biography and Net Worth

Director of Precigen

Ms. Agee has served as a Board member since July 2024. Ms. Agee is the Chief Executive Officer of Carilion Clinic, a health care organization, a position she has held since 2011. She previously served as President and Chief Executive Officer, Executive Vice President and Chief Operating Officer. Ms. Agee serves as a director on three other public company boards — Atlantic Union Bankshares Corp. (NYSE: AUB), where she has served since May 2024, RGC Resources, Inc. (NASDAQ: RGCO), where she has served since 2011, and Healthcare Realty Trust Incorporated (NYSE: HR), where she has served since 2018. She chairs the statewide economic development entity, Go VA, since 2020 and serves on the Governor’s advisory committee for revenue estimates, GACRE. She also chairs the Virginia Foundation for Independent Colleges and serves as Vice Chair of the Virginia Business Higher Education Council. She is a Fellow in the National Association of Corporate Directors. In January 2022, Ms. Agee was selected by newly inaugurated Virginia Governor Glenn Youngkin to serve on his Medical Advisory Team. She is also the former Chair of the American Hospital Association. Ms. Agee received a B.S. in Nursing from the University of Virginia, a Master of Science in Nursing from Emory University and attended the Kellogg School of Management, Northwestern University. She received honorary doctorate degrees from Roanoke College, Jefferson College of Health Sciences and the Virginia College of Osteopathic Medicine.

What is Nancy H. Agee's net worth?: The estimated net worth of Nancy H. Agee is at least $1.05 million as of September 4th, 2025. Agee owns 217,841 shares of Precigen stock worth more than $1,045,637 as of February 3rd. This net worth approximation does not reflect any other investments that Agee may own. Learn More about Nancy H. Agee's net worth.
How do I contact Nancy H. Agee?: The corporate mailing address for Agee and other Precigen executives is 20374 Seneca Meadows Parkway, Germantown MD, 20876. Precigen can also be reached via phone at (301) 556-9900 and via email at [email protected]. Learn More on Nancy H. Agee's contact information.
Has Nancy H. Agee been buying or selling shares of Precigen?: Nancy H. Agee has not been actively trading shares of Precigen during the past quarter. Most recently, on Thursday, September 4th, Nancy H. Agee bought 15,000 shares of Precigen stock. The stock was acquired at an average cost of $4.60 per share, with a total value of $69,000.00. Following the completion of the transaction, the director now directly owns 217,841 shares of the company's stock, valued at $1,002,068.60. Learn More on Nancy H. Agee's trading history.
Who are Precigen's active insiders?: Precigen's insider roster includes Nancy Agee (Director), Steven Frank (Director), Randal Kirk (Director), Donald Lehr (Insider), David Obstler (CFO), Jeffrey Perez (SVP), Helen Sabzevari (CEO), Rutul Shah (COO), and Harry Thomasian, Jr. (CFO). Learn More on Precigen's active insiders.
Are insiders buying or selling shares of Precigen?: In the last year, Precigen insiders bought shares 6 times. They purchased a total of 54,221 shares worth more than $214,466.77. In the last year, insiders at the biotechnology company sold shares 9 times. They sold a total of 11,850,608 shares worth more than $45,662,587.08. The most recent insider tranaction occured on December, 22nd when Director Randal J Kirk sold 1,900,036 shares worth more than $7,942,150.48. Insiders at Precigen own 47.1% of the company. Learn More about insider trades at Precigen.
Information on this page was last updated on 12/22/2025.

Nancy H. Agee Insider Trading History at Precigen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/4/2025	Buy	15,000	$4.60	$69,000.00	217,841
8/28/2025	Buy	10,645	$4.65	$49,499.25	202,841
8/19/2025	Buy	15,360	$3.20	$49,152.00	192,196

Nancy H. Agee Buying and Selling Activity at Precigen

Precigen Company Overview

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Today's Range

Now: $4.80

$4.59

$5.02

50 Day Range

MA: $4.19

$3.48

$4.85

2 Week Range

Now: $4.80

$1.11

$5.22

Volume

2,662,896 shs

Average Volume

3,599,735 shs

Market Capitalization

$1.70 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.07